Physician profile
Lorin Robert Press
NPI 1720082159
$2,197.08
in general payments reported to CMS, 2019-2025
21 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $254 · 2021: $477 · 2022: $336 · 2023: $223 · 2024: $209 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $716.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $426.40 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $345.35 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $258.35 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $193.57 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $166.90 | 2020-2022 | |
| Sight Sciences, INC. | $125.92 | 2023-2025 | Sion Surgical Instrument, Omni Surgical System, Tearcare System |
| Harrow Eye, LLC | $125.00 | 2024 | Vevye |
| Bausch & Lomb Americas INC. | $116.93 | 2022-2025 | Miebo, Scoutpro Osmolarity System |
| Abbvie INC. | $91.68 | 2022-2025 | |
| Eyevance Pharmaceuticals LLC | $69.49 | 2019-2022 | |
| Shire North American Group INC | $43.53 | 2019 | |
| Alcon Vision LLC | $35.21 | 2024 | Eysuvis |
| Tarsus Pharmaceuticals, INC. | $33.46 | 2024 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $32.22 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $32.09 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $23.11 | 2021 | |
| Thea Pharma INC. | $18.38 | 2025 | Iyuzeh |
| Amgen INC. | $15.34 | 2025 | Uplizna |
| Oyster Point Pharma, INC. | $15.16 | 2023 | Tyrvaya |
| Eyepoint US, INC. | $14.84 | 2021 | |
| Dompe US, INC. | $14.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorin Press listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.